Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed <i>rpoB</i> Mutations and Discordant Susceptibility Phenotypes-Reference-Cited by-同舟云学术

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes

Published:2022-02-23 Issue:1 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Wang Wei¹,Liu Rongmei²,Yao Cong¹,Huo Fengmin³,Shang Yuanyuan¹,Zhang Xuxia¹,Wang Yufeng⁴,Xue Zhongtan¹,Ma Liping²,Pang Yu¹^ORCID

Affiliation:

1. Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China

2. Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China

3. National Tuberculosis Clinical Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China

4. Innovation Alliance on Tuberculosis Diagnosis and Treatment, Beijing, People’s Republic of China

Abstract

Tuberculosis (TB) is still one of the world's leading infectious disease killers. The early and accurate diagnosis of RIF resistance is necessary to deliver timely and appropriate treatment for TB patients and improve their clinical outcome.

Funder

Beijing Hospital Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02087-21

Reference26 articles.

1. World Health Organization. 2021. WHO global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. MDR Tuberculosis — Critical Steps for Prevention and Control

3. Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

4. Study of the Rifampin Monoresistance Mechanism in Mycobacterium tuberculosis

5. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy;Microbiology Spectrum;2024-01-11

2. Insidious transmission of Mycobacterium tuberculosis in Ordos, China: a molecular epidemiology study;European Journal of Clinical Microbiology & Infectious Diseases;2023-12-06

3. Effects of sputum bacillary load and age on GeneXpert and traditional methods in pulmonary tuberculosis: a 4-year retrospective comparative study;BMC Infectious Diseases;2023-11-27

4. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies;Expert Review of Anti-infective Therapy;2023-05-08

5. Performance Evaluation of the BACTEC MGIT 960 System for Rifampin Drug-Susceptibility Testing of Mycobacterium tuberculosis Using the Current WHO Critical Concentration;Journal of Clinical Microbiology;2023-01-26